BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp Common stock

BGLC · NASDAQ · Basic Materials / Specialty Chemicals

0.821USD-0.09 (-9.43%)

Price History

Full chart

Market Stats

Previous Close0.9065
Open0.8731
Day Range0.821 – 0.89
52-Week Range1.07 – 5.89
Volume927
Market Cap4.34M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.26
Dividend Yield0.00%
Beta2.21
50-Day Avg1.51
200-Day Avg2.33

About

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Company Details

  • SectorBasic Materials
  • IndustrySpecialty Chemicals
  • CEOMr. Su-Leng Tan
  • Employees19
  • HeadquartersMenara UOA Bangsar, Kuala Lumpur, Malaysia, 59000, USA
  • Websitehttps://www.bionexusgenelab.com

Leadership

  • Mr. Su-Leng TanCEO, President, Secretary & Director · b. 1984
  • Ms. Set Fui ChongChief Financial Officer · b. 1963
  • Mr. Kwan Wah ChanMarketing Manager
  • Mr. Too Kam ThamManaging Director

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-107.68K212.33K126.95K11.39M13.36M10.93M9.77M9.51M7.42M
Growth (%)--+97.18%-40.21%+8872.03%+17.31%-18.21%-10.60%-2.66%-21.93%
Cost of Revenue-28.87K183.56K71.07K9.67M11.17M9.67M8.44M8.22M6.34M
Gross Profit-78.81K28.77K55.89K1.72M2.19M1.26M1.33M1.29M1.09M
Gross Margin-73.19%13.55%44.02%15.10%16.42%11.52%13.61%13.56%14.62%
Operating Expense-206.72K-31.14K331.59K446.00K1.14M1.55M3.92M2.86M4.24M
Operating Income-840-127.91K59.90K-275.70K1.27M1.06M-291.18K-2.59M-1.57M-3.16M
Operating Margin--118.79%28.21%-217.17%11.18%7.90%-2.66%-26.54%-16.55%-42.54%
EBITDA--104.38K100.51K-222.37K1.38M1.16M-185.76K-2.49M-1.42M-2.80M
EBITDA Margin--96.94%47.34%-175.16%12.08%8.71%-1.70%-25.43%-14.94%-37.67%
Net Income-835-123.75K26.45K-246.47K1.09M751.57K-355.97K-2.63M-1.60M-2.98M
Net Income Margin--114.92%12.46%-194.14%9.61%5.62%-3.26%-26.91%-16.81%-40.20%
R&D-------54.98K47.51K50.67K
R&D as % of Total Revenue-------0.56%0.50%0.68%
Interest Expense000011.31K12.97K12.48K13.93K21.15K19.54K
Interest Expense % of Total Revenue-0.00%0.00%0.00%0.10%0.10%0.11%0.14%0.22%0.26%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets261.27M1.65M1.23M10.12M9.57M8.74M11.40M10.43M9.25M
Total Liabilities1.34K1.18M130.31K108.87K3.45M2.39M2.08M1.74M2.11M637.86K
Total Equity-1.31K94.63K1.52M1.12M6.66M7.18M6.67M9.66M8.32M8.61M
Cash26839.14K659.24K859.08K2.79M2.12M2.12M5.93M4.38M2.38M
Total Debt--82.06K89.44K123.42K76.95K56.77K146.59K210.56K176.05K
Net Debt-26-839.14K-577.17K-769.64K-2.66M-2.05M-2.06M-5.78M-4.17M-2.21M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-835357.22K-274.08K-217.27K552.68K9.16K544.03K-1.76M-2.23M-1.84M
Investing Cash Flow-5.31M-5.31M-51.70K-12.82K1.32M-490.57K-450.50K-1.86M418.20K944.75K
Financing Cash Flow6385.78M742.94K-180.81K-4.95K-28.22K115.96K6.27M144.97K298.84K
Capital Expenditure0314.82K39.62K12.82K421.62K3.16K54.17K149.40K226.99K36.97K
Free Cash Flow-83542.40K-313.70K-230.09K131.06K6.00K489.86K-1.91M-2.46M-1.88M
Dividends Paid----6.31K22.04K0.12115.38K68.13K22.11K
FCF to OCF100.00%11.87%114.46%105.90%23.71%65.48%90.04%108.48%110.16%102.01%
Dividend Paid to FCF----4.81%367.33%0.00%-6.04%-2.77%-1.18%

Earnings

Report DateDec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024May 15, 2025Aug 18, 2025Nov 14, 2025Dec 31, 2025Mar 31, 2026Aug 14, 2026Nov 13, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.00----------------0.00-----
EPS Actual-0.000.01-0.00-0.00-0.00-0.00-0.00-0.00-0.000.01-0.000.000.010.000.000.000.060.01-0.10-0.05-0.11-0.05-0.18-1.560.17-0.060.11-0.75-0.19-0.03-0.34-0.40-0.52-0.22-0.12-
Surprise------------------------------------
Timing------------------------------------

Key Statistics & Ratios

Market Cap4.34M
Enterprise Value989.21K
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.39
Price / Book0.55
EPS-1.26
Book Value3.22
Revenue (TTM)3.13M
Gross Profit (TTM)385.89K
EBITDA-2.64M
Profit Margin-82.36%
Operating Margin-398.69%
Return on Equity-33.66%
Return on Assets-18.99%
Shares Outstanding2.93M
Shares Float1.67M
Beta2.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
0.49%
Insiders
44.72%
Retail / Other
54.79%

Top Institutional Holders

  • UBS Group AG
    2310.01%
  • Wells Fargo & Co
    10.00%
  • DRW Securities, LLC
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    2.37K0.10%

Stock Splits

  • Apr 7, 20251:10